Advancing Treatments Through Technology
Our immunotherapy technologies give patients a safe alternative to traditional treatments by increasing the body’s ability to recognize and fight tumor cells.
Our gene therapy platform utilizes Adeno-Associated Virus (AAV) technology for the treatment of cardiovascular diseases.
Theragene Pharmaceuticals is creating life-changing cancer and cardiology treatments through the development of our novel immunotherapy and Adeno-Associated Virus (AAV) gene therapy platforms. As a company operating in both the US and Asia, we deliver unique product development models, utilizing the strengths of each region, while delivering safe, effective treatments.
Our mission is to advance cutting-edge science through efficient development plans while pursuing licensing or co-development collaborations.